A big enhance of bile acid (BA) ranges has been acknowledged as a basic metabolic phenotype of numerous liver illnesses. Monitoring of BA profiles has been proposed for etiology differentiation on liver damage. Right here, we quantitatively profiled serum BAs of wholesome controls and 719 sufferers with persistent liver illness of 5 etiologies, hepatitis B virus (HBV), hepatitis C virus (HCV), nonalcoholic steatohepatitis (NASH), alcohol-induced liver illness (ALD), and first biliary cirrhosis (PBC), and investigated the generality and specificity of various etiologies. The uncooked knowledge have been deposited into MetaboLights (ID: MTBLS2459). We discovered that sufferers with HBV, HCV, and NASH seemed to be extra comparable, and ALD and PBC sufferers clustered collectively.
BA profiles, consisting of a complete focus of the 21 quantified BAs [total BAs (TBAs)], 21 BA proportions, and 24 BA related variables, have been extremely completely different among the many etiologies. Particularly, the full BAs was larger in ALD and PBC sufferers in contrast with the opposite three teams. The proportion of conjugated deoxycholates was the very best in HBV-infected sufferers. The ratio of 12α-hydroxylated (12α-OH) to non-12α-OH BAs was the very best in NASH sufferers. The proportion of taurine-conjugated BAs was the very best in ALD sufferers. For PBC sufferers, the proportion of ursodeoxycholate species was the very best, and the ratio of major to secondary BAs was the bottom.
Comparatively, the distinction of BA profiles amongst cirrhosis sufferers was constant however weaker than that of all sufferers. The correlations between BA profiles and scientific indices have been additionally fairly completely different in several pathological teams, each in all sufferers and in sufferers with cirrhosis. Total, our findings prompt that BA compositions are distinct amongst sufferers with completely different etiologies of persistent liver illness, and a few BA-relevant variables are of scientific potentials for liver damage kind differentiation, though additional validations on extra etiologies and populations are wanted.
Circulatory cadmium positively correlates with epithelial-mesenchymal transition in sufferers with persistent obstructive pulmonary illness
Environmental cadmium (Cd) publicity may cause a number of pulmonary illnesses. Epithelial-mesenchymal transition (EMT) concerned within the technique of persistent obstructive pulmonary illness (COPD). Nonetheless, the affiliation between environmental Cd publicity and EMT was unclear in COPD sufferers. This examine aimed to research the associations amongst circulatory Cd, EMT and COPD primarily based on case-control examine. 4 hundred COPD sufferers and 400 management topics have been recruited. Circulatory Cd was detected utilizing atomic adsorption spectrometer. MicroRNA-30 (miR-30) was measured by RT-PCR and the markers of pulmonary EMT have been evaluated by way of western blotting.
Circulatory Cd focus was elevated and serum miR-30 was decreased in COPD sufferers. Circulatory Cd was inversely related to pulmonary perform in COPD sufferers. Furthermore, serum miR-30 was regularly decreased in parallel with FEV1 in COPD sufferers. In the meantime, there was a unfavourable affiliation between serum miR-30 and circulatory Cd in COPD sufferers. Additional evaluation discovered that E-cadherin, certainly one of epithelial biomarkers, was diminished in lung tissues of COPD sufferers with larger circulatory Cd. Our outcomes present proof that miR-30 discount contributing to pulmonary EMT might contain within the technique of Cd-induced COPD.
Nationwide developments and outcomes of genetically inherited non-alcoholic persistent liver illness within the USA: estimates from the Nationwide Inpatient Pattern (NIS) database
Medical literature on the prevalence of genetic liver illness is missing. On this examine, we investigated the in-hospital healthcare and financial burden from genetic causes of non-alcoholic persistent liver illness (NACLD) and non-alcoholic liver cirrhosis (NALC) within the USA. Knowledge have been abstracted from the Nationwide Inpatient Pattern database between 2002 and 2014 utilizing ICD9 codes for sufferers discharged with NACLD and NALC secondary to genetic illnesses together with alpha-1 antitrypsin deficiency (A1ATd), cystic fibrosis (CF), Wilson illness (WD), hereditary hemochromatosis (HHC), glycogen storage illness, and issues of fragrant amino-acid metabolism (DAAAM).
All through the examine interval, there have been 19,332 discharges for NACLD related to the six genetic illnesses together with 14,368 for NALC. There have been $1.09 billion in hospital fees, 790 in-hospital deaths, and 955 liver transplants carried out. Total, A1ATd was related to 8,983 (62.52%) hospitalizations for NALC adopted by WD, CF, and HHC. The best in-hospital mortality was seen with HHC. The best frequency of liver transplants was seen with DAAAM. The variety of hospitalizations for genetic liver illnesses continues to extend. With elevated funding and directed analysis efforts, we are able to goal to enhance medical remedies and the standard of life for sufferers in danger for liver deterioration.
 ELISA Kit) Mini Samples Mouse Pulmonary Activation Regulated Chemokine (PARC) ELISA Kit |
|
MEB522Mu-5x96wellstestplate |
Cloud-Clone |
5x96-wells test plate |
EUR 2994.77 |
- The Intra-assay Precision is determined when 3 samples with low, middle and high level of Mini Samples Mouse Pulmonary Activation Regulated Chemokine (PARC) were tested on 3 different plates, 8 replicates in each plate
- CV(%) = SD/meanX100
- Intra-Ass
- Show more
|
|
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Mini Samples Mouse Pulmonary Activation Regulated Chemokine (PARC). |
Mini Samples Mouse Pulmonary Activation Regulated Chemokine (PARC) ELISA Kit |
|
4-MEB522Mu |
Cloud-Clone |
-
EUR 5574.00
-
EUR 2945.00
-
EUR 733.00
|
-
10 plates of 96 wells
-
5 plates of 96 wells
-
1 plate of 96 wells
|
- Known also as Pulmonary Activation Regulated Chemokine elisa. Alternative names of the recognized antigen: CCL18
- AMAC1
- SCYA18
- DCCK1
- MIP-4
- CKb7
- Alternative Macrophage Activation Associated CC Chemokine 1
- Chemokine C-C-Motif Ligand 18
- Macrophag
- Show more
|
|
Description: Enzyme-linked immunosorbent assay based on the Double-antibody Sandwich method for detection of Mini Samples Mouse Pulmonary Activation Regulated Chemokine (PARC) in samples from n/a with no significant corss-reactivity with analogues from other species. |
 2019-nCoV IgG/IgM RapiCard InstaTest for Whole Blood/Serum/Plasma samples |
|
GEN-176552-25tests |
Cortez Diagnostic |
25 tests |
EUR 276 |
|
Description: A rapid test for detection of antibodies (IgG and IgM) for 2019-nCoV, the novel Coronavirus from the Wuhan strain. The test is easy to perform, takes 10 minutes to provide reliable results and is higly specific to the 2019-nCoV Coronavirus. |
2019-nCoV IgG/IgM RapiCard InstaTest for Whole Blood/Serum/Plasma samples |
|
GEN-176552-50tests |
Cortez Diagnostic |
50 tests |
EUR 472 |
|
Description: A rapid test for detection of antibodies (IgG and IgM) for 2019-nCoV, the novel Coronavirus from the Wuhan strain. The test is easy to perform, takes 10 minutes to provide reliable results and is higly specific to the 2019-nCoV Coronavirus. |
 lysate) Human K562 (Chronic Myelogenous Leukemia) lysate |
|
HCL-1204 |
Alpha Diagnostics |
1 mg |
EUR 524 |
 ExoStep Plasma |
|
ExoS-25-P81 |
ImmunoStep |
25 test |
EUR 550.5 |
 EDTA plasma |
|
90-1009 |
Fitzgerald |
100 ml |
EUR 2028 |
|
Description: BNP and NT-proBNP free plasma EDTA |
 Donkey Plasma |
|
88R-D002 |
Fitzgerald |
100 ml |
EUR 111 |
|
Description: Control Donkey Plasma |
 Crohn's Disease Exosome |
|
P141-CR |
101Bio |
NULL |
EUR 0 |
 Marek Disease Virus Antibody |
|
abx022055-1mg |
Abbexa |
1 mg |
EUR 940 |
- Shipped within 5-10 working days.
|
Marek Disease Virus Antibody |
|
abx022056-1mg |
Abbexa |
1 mg |
EUR 940 |
- Shipped within 5-10 working days.
|
 Newcastle Disease Virus Antibody |
|
abx022111-1mg |
Abbexa |
1 mg |
EUR 940 |
- Shipped within 5-10 working days.
|
Newcastle Disease Virus Antibody |
|
abx022112-1mg |
Abbexa |
1 mg |
EUR 940 |
- Shipped within 5-10 working days.
|
Newcastle Disease Virus Antibody |
|
abx022113-1mg |
Abbexa |
1 mg |
EUR 940 |
- Shipped within 5-10 working days.
|
Newcastle Disease Virus Antibody |
|
abx022114-1mg |
Abbexa |
1 mg |
EUR 940 |
- Shipped within 5-10 working days.
|
Newcastle Disease Virus Antibody |
|
abx022115-1mg |
Abbexa |
1 mg |
EUR 899 |
- Shipped within 5-10 working days.
|
Newcastle Disease Virus Antibody |
|
abx022116-1mg |
Abbexa |
1 mg |
EUR 899 |
- Shipped within 5-10 working days.
|
Newcastle Disease Virus Antibody |
|
abx022117-1mg |
Abbexa |
1 mg |
EUR 940 |
- Shipped within 5-10 working days.
|
 Newcastle disease virus antibody |
|
10-7871 |
Fitzgerald |
500 ug |
EUR 317 |
|
Description: Mouse monoclonal Newcastle disease virus antibody |
Newcastle disease virus antibody |
|
10-7872 |
Fitzgerald |
500 ug |
EUR 317 |
|
Description: Mouse monoclonal Newcastle disease virus antibody |
Newcastle disease virus antibody |
|
10-7873 |
Fitzgerald |
500 ug |
EUR 581 |
|
Description: Mouse monoclonal Newcastle disease virus antibody |
Newcastle disease virus antibody |
|
10-7874 |
Fitzgerald |
500 ug |
EUR 581 |
|
Description: Mouse monoclonal Newcastle disease virus antibody |
 Bluetongue disease PCR kit |
|
PCR-V224-48R |
Bioingentech |
50T |
EUR 524.4 |
- Contact us in order to know the reactivity of the kit.
|
|
Description: An conventional PCR kit for detection of Bluetongue disease |
Bluetongue disease PCR kit |
|
PCR-V224-96R |
Bioingentech |
100T |
EUR 669.4 |
- Contact us in order to know the reactivity of the kit.
|
|
Description: An conventional PCR kit for detection of Bluetongue disease |
 Tyzzer's disease PCR kit |
|
PCR-V323-48D |
Bioingentech |
50T |
EUR 425.8 |
- Contact us in order to know the reactivity of the kit.
|
|
Description: An conventional PCR kit for detection of Tyzzer's disease |
Tyzzer's disease PCR kit |
|
PCR-V323-96D |
Bioingentech |
100T |
EUR 521.5 |
- Contact us in order to know the reactivity of the kit.
|
|
Description: An conventional PCR kit for detection of Tyzzer's disease |
 Crohn's Disease Exosome RNA |
|
P241-CR |
101Bio |
NULL |
EUR 0 |
 Human Plasma Fibronectin |
|
FB001 |
Neuromics |
1 mg |
EUR 466 |
 ExoStepTM Plasma + Standard |
|
ExoS-25-PST81 |
ImmunoStep |
25 test |
EUR 726 |
) Dog Plasma (Heparin) |
|
abx098253-50ml |
Abbexa |
50 ml |
EUR 495 |
- Shipped within 5-10 working days.
|
 Lithium Heparin Plasma |
|
90-1016 |
Fitzgerald |
100 ml |
EUR 370 |
|
Description: Lithium Heparin Human Plasma Sterile filtered |
) Rabbit Plasma (EDTA) |
|
88R-1029E |
Fitzgerald |
500 ml |
EUR 230 |
|
Description: Sterile Rabbit Plasma with EDTA |
 Chylomicrons, Human Plasma |
|
7285-1000 |
Biovision |
|
EUR 501 |
 Apotransferrin, Mouse Plasma |
|
7540-1000 |
Biovision |
|
EUR 272 |
 Apotransferrin, Rat Plasma |
|
7541-1000 |
Biovision |
|
EUR 370 |
 Transferrin, Rat Plasma |
|
7543-1000 |
Biovision |
|
EUR 251 |
 Hemopexin, Human Plasma |
|
7544-1000 |
Biovision |
|
EUR 572 |
 Albumin, Human Plasma |
|
7546-1 |
Biovision |
|
EUR 240 |
 Plasminogen, Human Plasma |
|
7549-1 |
Biovision |
|
EUR 283 |
 Prothrombin, Human Plasma |
|
7684-1 |
Biovision |
|
EUR 180 |
 Prekallikrein, Human Plasma |
|
7685-100 |
Biovision |
|
EUR 224 |
 Apotransferrin, Human Plasma |
|
4707-100 |
Biovision |
|
EUR 169 |
 Vitronectin, Human Plasma |
|
4087-100 |
Biovision |
|
EUR 457 |
 Plasmin, Human Plasma |
|
4089-1000 |
Biovision |
|
EUR 272 |
 Kallikrein, Human Plasma |
|
4093-50 |
Biovision |
|
EUR 272 |
 Ceruloplasmin, Human Plasma |
|
4096-1000 |
Biovision |
|
EUR 229 |
 De-Plasma™ |
|
D022-1x25MG |
TOKU-E |
1 x 25 mg |
EUR 77 |
De-Plasma™ |
|
D022-5x25MG |
TOKU-E |
5 x 25 mg |
EUR 127 |
Ceruloplasmin, Human Plasma |
|
P1452-1 |
Biovision |
|
EUR 479 |
 (ZAP70/2035) Antibody) ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|
BNC552035-100 |
Biotium |
100uL |
EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF555 conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|
BNC552035-500 |
Biotium |
500uL |
EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF555 conjugate, Concentration: 0.1mg/mL |
 (ZAP70/2046) Antibody) ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|
BNC552046-100 |
Biotium |
100uL |
EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF555 conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|
BNC552046-500 |
Biotium |
500uL |
EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF555 conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|
BNC612035-100 |
Biotium |
100uL |
EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF660R conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|
BNC612035-500 |
Biotium |
500uL |
EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF660R conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|
BNC612046-100 |
Biotium |
100uL |
EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF660R conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|
BNC612046-500 |
Biotium |
500uL |
EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF660R conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|
BNC402035-100 |
Biotium |
100uL |
EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF640R conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|
BNC402035-500 |
Biotium |
500uL |
EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF640R conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|
BNC402046-100 |
Biotium |
100uL |
EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF640R conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|
BNC402046-500 |
Biotium |
500uL |
EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF640R conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|
BNC472035-100 |
Biotium |
100uL |
EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF647 conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|
BNC472035-500 |
Biotium |
500uL |
EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF647 conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|
BNC472046-100 |
Biotium |
100uL |
EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF647 conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|
BNC472046-500 |
Biotium |
500uL |
EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF647 conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|
BNC052035-100 |
Biotium |
100uL |
EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF405M conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|
BNC052035-500 |
Biotium |
500uL |
EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF405M conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|
BNC052046-100 |
Biotium |
100uL |
EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF405M conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|
BNC052046-500 |
Biotium |
500uL |
EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF405M conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|
BNC042035-100 |
Biotium |
100uL |
EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF405S conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|
BNC042035-500 |
Biotium |
500uL |
EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF405S conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|
BNC042046-100 |
Biotium |
100uL |
EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF405S conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|
BNC042046-500 |
Biotium |
500uL |
EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF405S conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|
BNC432035-100 |
Biotium |
100uL |
EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF543 conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|
BNC432035-500 |
Biotium |
500uL |
EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF543 conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|
BNC432046-100 |
Biotium |
100uL |
EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF543 conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|
BNC432046-500 |
Biotium |
500uL |
EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF543 conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|
BNUB2035-100 |
Biotium |
100uL |
EUR 264 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), Concentration: 0.2mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|
BNUB2035-50 |
Biotium |
50uL |
EUR 405 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), 1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|
BNUB2035-500 |
Biotium |
500uL |
EUR 513 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), Concentration: 0.2mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|
BNUB2046-100 |
Biotium |
100uL |
EUR 264 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), Concentration: 0.2mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|
BNUB2046-50 |
Biotium |
50uL |
EUR 405 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), 1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|
BNUB2046-500 |
Biotium |
500uL |
EUR 513 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), Concentration: 0.2mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|
BNC682035-100 |
Biotium |
100uL |
EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF568 conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|
BNC682035-500 |
Biotium |
500uL |
EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF568 conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|
BNC682046-100 |
Biotium |
100uL |
EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF568 conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|
BNC682046-500 |
Biotium |
500uL |
EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF568 conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|
BNC702035-100 |
Biotium |
100uL |
EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF770 conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|
BNC702035-500 |
Biotium |
500uL |
EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF770 conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|
BNC702046-100 |
Biotium |
100uL |
EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF770 conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|
BNC702046-500 |
Biotium |
500uL |
EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF770 conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|
BNC882035-100 |
Biotium |
100uL |
EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF488A conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|
BNC882035-500 |
Biotium |
500uL |
EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF488A conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|
BNC882046-100 |
Biotium |
100uL |
EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF488A conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|
BNC882046-500 |
Biotium |
500uL |
EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF488A conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|
BNC942035-100 |
Biotium |
100uL |
EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF594 conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|
BNC942035-500 |
Biotium |
500uL |
EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF594 conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|
BNC942046-100 |
Biotium |
100uL |
EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF594 conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|
BNC942046-500 |
Biotium |
500uL |
EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF594 conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|
BNCB2035-100 |
Biotium |
100uL |
EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), Biotin conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|
BNCB2035-500 |
Biotium |
500uL |
EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), Biotin conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|
BNCB2046-100 |
Biotium |
100uL |
EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), Biotin conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|
BNCB2046-500 |
Biotium |
500uL |
EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), Biotin conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|
BNCH2035-100 |
Biotium |
100uL |
EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|
BNCH2035-500 |
Biotium |
500uL |
EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|
BNCH2046-100 |
Biotium |
100uL |
EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|
BNCH2046-500 |
Biotium |
500uL |
EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|
BNC802035-100 |
Biotium |
100uL |
EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF680 conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|
BNC802035-500 |
Biotium |
500uL |
EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF680 conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|
BNC802046-100 |
Biotium |
100uL |
EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF680 conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|
BNC802046-500 |
Biotium |
500uL |
EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF680 conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|
BNCP2035-250 |
Biotium |
250uL |
EUR 394 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), PerCP conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|
BNCP2046-250 |
Biotium |
250uL |
EUR 394 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), PerCP conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|
BNCR2035-250 |
Biotium |
250uL |
EUR 394 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), RPE conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|
BNCR2046-250 |
Biotium |
250uL |
EUR 394 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), RPE conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|
BNCA2035-250 |
Biotium |
250uL |
EUR 394 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), APC conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|
BNCA2046-250 |
Biotium |
250uL |
EUR 394 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), APC conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|
BNCAP2035-100 |
Biotium |
100uL |
EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|
BNCAP2035-500 |
Biotium |
500uL |
EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|
BNCAP2046-100 |
Biotium |
100uL |
EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|
BNCAP2046-500 |
Biotium |
500uL |
EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|
BNC812035-100 |
Biotium |
100uL |
EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF680R conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|
BNC812035-500 |
Biotium |
500uL |
EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF680R conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|
BNC812046-100 |
Biotium |
100uL |
EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF680R conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|
BNC812046-500 |
Biotium |
500uL |
EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF680R conjugate, Concentration: 0.1mg/mL |
 Monoclonal Antibody) Anti-ZAP70 (Chronic Lymphocytic Leukemia Marker) Monoclonal Antibody |
|
M00754-1 |
BosterBio |
100ug/vial |
EUR 397 |
|
Description: Mouse Monoclonal ZAP70 (Chronic Lymphocytic Leukemia Marker) Antibody. Validated in IHC and tested in Human. |
 ELISA Kit) Human Plasma Renin Activity(Plasma Renin Activity) ELISA Kit |
|
QY-E05530 |
Qayee Biotechnology |
96T |
EUR 361 |
 cDNA from Pulmonary Embolism: Lung |
|
C1236152Ld-5 |
Biochain |
40 reactions |
EUR 811 |
|
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
 Immortalized Human Pulmonary Fibroblasts Cells |
|
T0490 |
ABM |
1x106 cells / 1.0 ml |
Ask for price |
Polycystic ovary syndrome (PCOS) is likely one of the commonest ovarian illnesses amongst ladies of reproductive age. The reproductive and metabolic traits of PCOS are underpinned by adipocyte dysfunction, particularly diminished adiponectin secretion. Based mostly on proof that niacin stimulates adiponectin secretion, this examine evaluated the results of niacin on adiponectin concentrations and reproductive traits in a rat mannequin of PCOS. PCOS was induced by single injection of 4mg kg-1 oestradiol valerate (i.m.), and PCOS teams have been administered orally with saline or niacin (10 or 25mg kg-1) every day for 30 days after PCOS induction.
